Sun Pharma expects normalisation of India business in FY'19

In a message to shareholders in the company's Annual Report for 2017-18, Sun Pharma managing director Dilip Shanghvi however said the government's enforced price cuts and policy changes are potential risk factors for the business.

from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/2NhfeNz